DOCSLIB.ORG

Natural Products and Combinatorial Chemistry: Back to the Future Jean-Yves Ortholand1 and a Ganesan2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Natural Products and Combinatorial Chemistry: Back to the Future Jean-Yves Ortholand1 and a Ganesan2 Natural products and combinatorial chemistry: back to the future Jean-Yves Ortholand1 and A Ganesan2 The introduction of high-throughput synthesis and combinatorial enabled the design and synthesis of sophisticated drug chemistry has precipitated a global decline in the screening molecules. By the 1950s, such purely synthetic medicines of natural products by the pharmaceutical industry. Some were on an equal footing with their natural product companies terminated their natural products program, despite counterparts. Nevertheless, natural products were still the unproven success of the new technologies. This was a considered a valuable source of drug leads, and the testing premature decision, as natural products have a long history of of natural product extracts was widely practiced in the providing important medicinal agents. Furthermore, they pharmaceutical industry [2,3]. The situation has chan- occupy a complementary region of chemical space compared ged dramatically within the past 20 years. With high- with the typical synthetic compound library. For these reasons, throughput screening (HTS), assay speed far outpaced the interest in natural products has been rekindled. Various the rate of compound supply for the first time — a state of approaches have evolved that combine the power of natural affairs that fuelled the birth of combinatorial chemistry. products and organic chemistry, ranging from the The promise of a seemingly inexhaustible supply of combinatorial total synthesis of analogues to the exploration compound libraries precipitated a further shift away from of natural product scaffolds and the design of completely natural products, and many companies terminated their unnatural molecules that resemble natural products in their efforts in this direction. Here, we review the rationale molecular characteristics. behind this strategic decision, and highlight reasons why natural products are coming back into fashion [4,5–7]. Addresses 1Merck Sante´ , 115 Avenue Lacassagne, 69003 Lyon, France The early days of combinatorial chemistry: e-mail: [email protected] paradise lost 2School of Chemistry, University of Southampton, Southampton SO17 1BJ, UK While the past value of screening natural product extracts e-mail: [email protected] is indisputable, it is equally true that it is associated with several drawbacks, chiefly: Current Opinion in Chemical Biology 2004, 8:271–280 1. Expense. Building up and maintaining a high-quality This review comes from a themed issue on collection of natural product extracts is expensive. Combinatorial chemistry This is why it was traditionally undertaken by big Edited by A Ganesan and Anthony D Piscopio pharma or large organizations such as the National Cancer Institute (NCI), and beyond the reach of Available online 6th May 2004 smaller biotech or startup companies. 1367-5931/$ – see front matter 2. Time. Once a hit is identified from an extract, bioas- ß 2004 Elsevier Ltd. All rights reserved. say-guided fractionation is needed to identify the active component. This time-consuming process is DOI 10.1016/j.cbpa.2004.04.011 not always compatible with the present regime of ‘blitz’ screening campaigns where assay support is Abbreviations available for a limited duration. ACD Available Chemicals Database HDAC histone deacetylase 3. Novelty. Once the active component is isolated, its HTS high-throughput screening novelty is unpredictable and requires a further expen- SAR structure–activity relationship diture of time for characterization. In the worst-case scenario, the lead may turn out to be a well-known natural product that cannot be patented, or one already Introduction protected by a competitor. Meanwhile, if it is a novel Since time immemorial, mankind has sourced the flora natural product, full structural elucidation can be a and fauna around him to ameliorate disease. The accu- lengthy exercise. mulated wisdom (if you like, from a worldwide combi- 4. Tractability. Natural products are often structurally natorial search of natural product space) of folklore complex. With such molecules, deriving meaningful provided the mainstay of our pharmacopeia for centuries structure–activity relationships (SARs) or identifying a [1]. In the past 100 years, this dependence was irreversibly pharmacophore is a significant hurdle for the medic- broken for two reasons. Firstly, advances in biology began inal chemist. Even a natural product of low to medium to provide insight into the molecular mechanisms under- complexity is likely to lose out to a similarly potent hit lying diseases, suggesting rational targets for therapeutic of synthetic origin, as the latter comes with a prepara- intervention. Secondly, advances in organic chemistry tive route already in place. www.sciencedirect.com Current Opinion in Chemical Biology 2004, 8:271–280 272 Combinatorial chemistry 5. Scale-up. The natural product lead is usually a minor as well as avoiding non-selective or promiscuous inhibi- component of the extract. Obtaining further quantities tors [13,14,15]. Tremendous advances in analytical requires large-scale reacquisition or refermentation, chemistry have enabled the routine high-throughput and can be a limiting factor for progression to pre- purification of compounds by mass-triggered preparative clinical development. liquid chromatography [16,17]. We are starting to see drug 6. Intellectual property. Countries are increasingly pro- candidates impacted by combinatorial chemistry in either tective of their biodiversity, and many do not authorize the discovery or optimization phase [18,19]. In the future, collection of natural product samples without prior it will probably be difficult to point to any synthetic drugs sanction. Should a drug candidate arise, negotiating that did not benefit from modern high-throughput tech- intellectual property rights and determining a reason- nologies at some stage of the process from lead discovery able share for the foreign country is a complex affair. to the clinic. Given these issues, the siren call of combinatorial chem- Although the quality of leads discovered directly from a istry proved too seductive. Although the technology was combinatorial library is steadily increasing, it is clear that in its infancy and had no track record, its potential to parallel synthesis is even more powerful at the lead rapidly deliver very large numbers of novel compounds optimization phase, when a series of related compounds was persuasive to management. Combinatorial libraries needs to be made and tested rapidly. The real issue then began to compete with, and then overtake, natural pro- is where the initial leads are going to come from. Does duct extracts for screening resources. Organizations such screening natural products interrogate a unique and as GlaxoWellcome, SmithKlineFrench, and Pfizer, whose complementary region of chemical space compared with product portfolio was predominantly based on synthetic that of synthetic compounds? Several groups from big drugs, eventually phased out natural product screening pharma — Bayer [20] and Roche [21], as well as smaller altogether. Others such as Merck and Novartis, with companies New Chem Entities [22] and SignalGene recent blockbuster natural products such as mevinolin [23], have attempted to answer this question by statis- and cyclosporin, respectively, have continued to maintain tical comparisons between therapeutically relevant mole- a presence in the area. cules and natural product collections. While the databases and computational methods used varied in each study, Natural products redux, or paradise regained the overall conclusions are remarkably convergent The global repercussions of the crisis in natural product (Table 1). In terms of Lipinski’s ‘Rule of Five’, it is clear screening were considerable, and appeared to herald a that the properties of the average natural product or drug permanent fall from grace. However, there has been a are quite similar. The Roche study, for example, found welcome reassessment recently, and a growing recogni- that 10% of trade drugs contained two or more violations tion that it was premature to abandon natural products in of the rules, as opposed to 12% for the natural products drug discovery. First and foremost, the promised ava- database. lanche of new drugs from high-throughput technologies such as combinatorial chemistry has yet to materialize. In How do natural products differ from drugs? They tend to fact, the number of new chemical entities reaching the contain a different molecular composition, containing market reached a two-decade minimum in 2002, with fewer nitrogen, halogen or sulfur atoms on average, but only a marginal improvement in 2003. are considerably more oxygen-rich, and contain more hydrogen bond donors. Compared with drugs or synthetic The reasons for the continuous decline of productivity compounds, they are likely to contain a larger number of within the pharmaceutical industry are complex and rings, significantly more chiral centres, and have sp3 controversial. The perceived failure of combinatorial hybridised bridgehead atoms present. Overall, natural chemistry, for example, was primarily due to unrealistic expectations. Provided a large enough library was Table 1 screened, it was assumed that useful leads would emerge, causing an unhealthy emphasis on compound numbers Mean values for a selection of molecular properties among natural, drug and synthetic compounds. rather than quality or purity. The actual composition of Natural Drugsa Syntheticsa the early libraries
Load more

Recommended publications
  • Phytochemistry and Pharmacogenomics of Natural Products Derived from Traditional Chinese Medicine and Chinese Materia Medica with Activity Against Tumor Cells
    152 Phytochemistry and pharmacogenomics of natural products derived from traditional chinese medicine and chinese materia medica with activity against tumor cells Thomas Efferth,1 Stefan Kahl,2,3,6 Kerstin Paulus,4 Introduction 2 5 3 Michael Adams, Rolf Rauh, Herbert Boechzelt, Cancer is responsible for 12% of the world’s mortality and Xiaojiang Hao,6 Bernd Kaina,5 and Rudolf Bauer2 the second-leading cause of death in the Western world. 1 Limited chances for cure by chemotherapy are a major German Cancer Research Centre, Pharmaceutical Biology, contributing factor to this situation. Despite much progress Heidelberg, Germany; 2Institute of Pharmaceutical Sciences, University of Graz; 3Joanneum Research, Graz, Austria; 4Institute in recent years,a key problem in tumor therapy with of Pharmaceutical Biology, University of Du¨sseldorf, Du¨sseldorf, established cytostatic compounds is the development of Germany; 5Institute of Toxicology, University of Mainz, Mainz, 6 drug resistance and threatening side effects. Most estab- Germany; and State Key Laboratory of Phytochemistry and Plant lished drugs suffer from insufficient specificity toward Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China tumor cells. Hence,the identification of improved anti- tumor drugs is urgently needed. Several approaches have been delineated to search for Abstract novel antitumor compounds. Combinatorial chemistry,a The cure from cancer is still not a reality for all patients, technology conceived about 20 years ago,was envisaged as which is mainly due to the limitations of chemotherapy a promising strategy to this demand. The expected surge in (e.g., drug resistance and toxicity). Apart from the high- productivity,however,has hardly materialized (1).
    [Show full text]
  • Virtual Screening for the Discovery of Bioactive Natural Products by Judith M
    Progress in Drug Research, Vol. 65 (Frank Petersen and René Amstutz, Eds.) © 2008 Birkhäuser Ver lag, Basel (Swit zer land) Virtual screening for the discovery of bioactive natural products By Judith M. Rollinger1, Hermann Stuppner1,2 and Thierry Langer2,3 1Institute of Pharmacy/Pharmacog- nosy, Leopold-Franzens University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria 2Inte:Ligand GmbH, Software Engineering and Consulting, Clemens Maria Hofbauergasse 6, 2344 Maria Enzersdorf, Austria 3Institute of Pharmacy/Pharmaceu- tical Chemistry/Computer Aided Molecular Design Group, Leopold- Franzens University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria <[email protected]> Virtual screening for the discovery of bioactive natural products Abstract In this survey the impact of the virtual screening concept is discussed in the field of drug discovery from nature. Confronted by a steadily increasing number of secondary metabolites and a growing number of molecular targets relevant in the therapy of human disorders, the huge amount of information needs to be handled. Virtual screening filtering experiments already showed great promise for dealing with large libraries of potential bioactive molecules. It can be utilized for browsing databases for molecules fitting either an established pharma- cophore model or a three dimensional (3D) structure of a macromolecular target. However, for the discovery of natural lead candidates the application of this in silico tool has so far almost been neglected. There are several reasons for that. One concerns the scarce availability of natural product (NP) 3D databases in contrast to synthetic libraries; another reason is the problematic compatibility of NPs with modern robotized high throughput screening (HTS) technologies.
    [Show full text]
  • Combinatorial and High-Throughput Screening of Materials Libraries: Review of State of the Art Radislav Potyrailo*
    REVIEW pubs.acs.org/acscombsci Combinatorial and High-Throughput Screening of Materials Libraries: Review of State of the Art Radislav Potyrailo* Chemistry and Chemical Engineering, GE Global Research Center, Niskayuna, New York 12309, United States Krishna Rajan Department of Materials Science and Engineering and Institute for Combinatorial Discovery, Iowa State University, Ames, Iowa 50011, United States Klaus Stoewe Universit€at des Saarlandes, Technische Chemie, Campus C4.2, 66123, Saarbruecken, Germany Ichiro Takeuchi Department of Materials Science and Engineering, University of Maryland, College Park, Maryland 20742, United States Bret Chisholm Center for Nanoscale Science and Engineering and Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, North Dakota 58102, United States Hubert Lam Chemistry and Chemical Engineering, GE Global Research Center, Niskayuna, New York 12309, United States ABSTRACT: Rational materials design based on prior knowledge is attractive because it promises to avoid time-consuming synthesis and testing of numerous materials candidates. However with the increase of complexity of materials, the scientific ability for the rational materials design becomes progressively limited. As a result of this complexity, combinatorial and high-throughput (CHT) experimentation in materials science has been recognized as a new scientific approach to generate new knowledge. This review demonstrates the broad applicability of CHT experimentation technologies in discovery and optimiza- tion of new materials. We discuss general principles of CHT materials screening, followed by the detailed discussion of high-throughput materials characteriza- tion approaches, advances in data analysis/mining, and new materials develop- ments facilitated by CHT experimentation. We critically analyze results of materials development in the areas most impacted by the CHT approaches, such as catalysis, electronic and functional materials, polymer-based industrial coatings, sensing materials, and biomaterials.
    [Show full text]
  • Combinatorial Chemistry: a Guide for Librarians
    City University of New York (CUNY) CUNY Academic Works Publications and Research City College of New York 2002 Combinatorial Chemistry: A Guide for Librarians Philip Barnett CUNY City College How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/cc_pubs/266 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] Issues in Science and Technology Librarianship Winter 2002 DOI:10.5062/F4DZ0690 URLs in this document have been updated. Links enclosed in{curly brackets} have been changed. If a replacement link was located, the new URL was added and the link is active; if a new site could not be identified, the broken link was removed. Combinatorial Chemistry: A Guide for Librarians Philip Barnett Associate Professor and Science Reference Librarian Science/Engineering Library City College of New York (CUNY) [email protected] Abstract In the 1980s a need to synthesize many chemical compounds rapidly and inexpensively spawned a new branch of chemistry known as combinatorial chemistry. While the techniques of this rapidly growing field are used primarily to find new candidate drugs, combinatorial chemistry is also finding other applications in various fields such as semiconductors, catalysts, and polymers. This guide for librarians explains the basics of combinatorial chemistry and elucidates the key information sources needed by combinatorial chemists. Introduction Most librarians who serve chemists or chemistry students are familiar with the six main disciplines of chemistry. These are: Physical chemistry applies the fundamental laws of physics, such as thermodynamics, electricity, and quantum mechanics, to explain chemical behavior.
    [Show full text]
  • Macrae/LC/Mcdowall
    1074 LCGC VOLUME 18 NUMBER 10 OCTOBER 2000 www.chromatographyonline.com Chromatography Data Systems in Drug Discovery The author discusses the roles of mass spectrometry and chromatography data systems within drug discovery analytical laboratories. He also presents ways of using laboratory information management systems to integrate the chemical data. n this article I’ll examine the use of • liquid chromatography–mass spectrome- chromatography data systems in drug try (LC–MS), which is used to determine discovery. Of particular interest is ana- compound identity based on the predic- I lyzing the results of the chemical soups tion from the anticipated compound to be produced by combinatorial chemistry labo- synthesized ratories. • nuclear magnetic resonance spectroscopy, The problem is that chromatographers which serves as a backup for compound working in combinatorial chemistry can be identification and is used mainly at the in a no-win situation: the combinatorial start of the library synthesis. chemistry increases throughput, and the I’ll concentrate on HPLC and MS analy- result is that the number of samples to be sis and on the data systems used to manage assayed also increases. How can this work the data produced. If analysts in small labo- flow be managed? What can chromatogra- ratories synthesize more than 100,000 com- phers do to reduce the waiting times? One pounds per year, they generally will need to idea, presented by Sage and co-workers (1), interpret one chromatogram and one spec- is to use parallel analysis with an eight- trum per compound. Still printing on paper? channel multiplexed electrospray interface That’s a lot of trees.
    [Show full text]
  • Combinatorial Chemistry-Parallel Synthesis 1. Introduction: the Drug Discovery Process
    Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis Agenda 1. Introduction: The Drug Discovery Process 2. Lead Discovery and Lead Optimization-Drugability -Drug-like molecules-the rule of 5 -Drug-like vs lead-like: the rule of 3 -Privileged scaffolds -Unwanted properties: frequent hitters-aggregate forming molecules 3. Combinatorial and Parallel Synthesis in Medicinal Chemistry -Historical background-objective -Compound mixtures versus single compounds -Solid phase synthesis versus synthesis in solution 4. Combinatorial Synthesis of Biopolymers -Polypeptides -Peptoids, Oligoureas, Oligocarbamates -Oligosaccharides -Oligonucletides, Oligonucleosides winter semester 09 Daniel Obrecht, Polyphor Ltd 1 Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis Agenda 4. Combinatorial synthesis of Biopolymers (cont.) -Combinatorial synthesis-split-mixed synthesis -Tagging strategies 5. Strategies for the Synthesis of Small Molecule Libraries -Library synthesis planning -Synthesis strategies -Classical multi-component reactions (MCR’s) -Sequential multi-component reactions (SMCR’s) -Fragment-based lead discovery -Dynamic Combinatorial Synthesis; Target-guided synthesis (TGS) -Disulfide thethering -Click chemistry -Building blocks -Parallel and/or combinatorial synthesis -Parallel work-up winter semester 09 Daniel Obrecht, Polyphor Ltd 2 Medicinal Chemistry: Combinatorial Chemistry-Parallel Synthesis Agenda 6. Applications of Parallel Synthesis and Combinatorial Chemistry in Medicinal Chemistry: Case Studies -Drug targets 7.
    [Show full text]
  • Combinatorial Chemistry: Concepts, Strategies and Applications
    Trum. Natl. A cod Sci. & Tec•h., J'hilippmt:s (200 I) 23: 215-238 COMBINATORIAL CHEMISTRY: CONCEPTS, STRATEGIES AND APPLICATIONS EVELYN B. RODRIGUEZ fnstit11le of Chemistry University ofthe Philippines Los Banos College, Laguna 4031 ABSTRACT Combinatorial chem1suy started with Mcrrilield's Nobel Pri.Ge wi11111ng 1nven11on­ the solid-phase synthesis of peptides. By mid I !J80s. solid phase techniques hove been gn:atly refined so that it wns possible to make huge numbers of peptides simultaneously in the same re:u;tion vessel. using a few steps. Later, stntegies and techniques of solution phase combinatorial synthesis have been developed as well. While solid phase synthesis makes it e11sier to conduct muhi-s1ep reactions and 10 dnvc reactions to compleuon. soluuon phnse synthesis allows a much wider range of organic reactions In its earliest form. the primary objective of combinatorial chemistry was to generate large .. librarics"of molecules en masse - instead of synthesizing compounds one by uni:. as how synthetic organic chcm1s1ry h:is been practiced for the last 100 years· and ho~ to !ind the most promising "lead" pharmaceutical compounds by high throughput screening of the libraries. Although combinatorial chemistry and combinatorial technology have been mostly applied to drug and agrochemical discovery. they can be powerful tools in the diagnostic. down- stream processing. catalysis and new m3lerials sector. INTRODUCTION Combinatorial chemistry (CC) is a set of techniques for creating simultaneously a multiplicity of compounds and then testing them for various kinds of activity. It started in the early 1980s with solid-phase peptide synthesis, although it was not called combinatorial chemistry until the earl y I 990s.
    [Show full text]
  • Combinatorial Chemistry in Ethnopharmacology
    try mis & A e p h p C l i n c r a e t WM Yuen, Mod Chem appl 2013, 1:1 i d o n o s M Modern Chemistry & Applications DOI: 10.4172/2329-6798.1000e104 ISSN: 2329-6798 Editorial Open Access Combinatorial Chemistry in Ethnopharmacology John WM Yuen* School of Nursing, The Hong Kong Polytechnic University, Yuk Choi Road, Hung Hom, Kowloon, Hong Kong Special Administrative Region, Hong Kong Biodiversity of natural products supplies an enormous source of drug Vast amount of data generated from major research contributions discovery leads. It is the general belief that the nature of natural products must be recorded and assessable by building libraries of medicinal are highly likely to provide therapeutic hits, because there are a greater chemistry. It is the truth that medicinal chemistry space is expanding number of stereocentres that intensifies scaffold diversity as supplied due to the continuous efforts in screening and testing many herbs and by the organic structures of more fused, bridged and spirocarbocyclic herbal formulations. Currently, several existing botanical databases rings [1]. The successful isolation of resveratrol from grapes has have retained chemical structure and phytochemical data of traditional remarked the benefits in promoting metabolic health by consuming red Chinese medicine, but many of these data are overlapping and in a wines, suggesting the pharmaceutical values as a potential treatment for non-standardized infrastructure format [12]. More importantly, none metabolic syndromes [2]. There are approximately 40% of all medicines of these databases contains biological information that is significant especially, 60% of anticancer agents and 80% of antimicrobials available for determining the bioactivity of chemical compounds.
    [Show full text]
  • Small and Random Peptides: an Unexplored Reservoir of Potentially Functional Primitive Organocatalysts
    Review Small and Random Peptides: An Unexplored Reservoir of Potentially Functional Primitive Organocatalysts. The Case of Seryl-Histidine Rafal Wieczorek 1, Katarzyna Adamala 2, Tecla Gasperi 3, Fabio Polticelli 3,4 and Pasquale Stano 5,* 1 Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland; [email protected] 2 Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] 3 Department of Science, Roma Tre University, Viale G. Marconi 446, 00146 Rome, Italy; [email protected] (T.G.); [email protected] (F.P.) 4 National Institute of Nuclear Physics, Roma Tre Section, Via della Vasca Navale 84, 00146 Rome, Italy 5 Department of Biological and Environmental Sciences and Technologies (DiSTeBA), University of Salento, Campus Ecotekne (S.P. 6 Lecce-Monteroni), 73100 Lecce, Italy * Correspondence: [email protected]; Tel.: +39-0832-298709; Fax: +39-0832-298732 Academic Editor: Pier Luigi Luisi Received: 5 February 2017; Accepted: 5 April 2017; Published: 9 April 2017 Abstract: Catalysis is an essential feature of living systems biochemistry, and probably, it played a key role in primordial times, helping to produce more complex molecules from simple ones. However, enzymes, the biocatalysts par excellence, were not available in such an ancient context, and so, instead, small molecule catalysis (organocatalysis) may have occurred. The best candidates for the role of primitive organocatalysts are amino acids and short random peptides, which are believed to have been available in an early period on Earth. In this review, we discuss the occurrence of primordial organocatalysts in the form of peptides, in particular commenting on reports about seryl-histidine dipeptide, which have recently been investigated.
    [Show full text]
  • A Review on Combinatorial Chemistry
    Research & Reviews: Journal of Chemistry e-ISSN:2319-9849 p-ISSN:2322-00 A Review on Combinatorial Chemistry Shaikh SM1*, Nalawade2, Shete AS1 and Doijad RC1 1Department of Pharmaceutics and Quality Assurance, Shree Santkrupa College of Pharmacy, Ghogaon, Karad, Maharashtra, India 2Appasaheb Birnale College of Pharmacy, Sangli, Maharashtra, India Review Article Received date: 02/04/2016 ABSTRACT Accepted date: 13/04/2017 Present review article is the study on the combinatorial chemistry. Published date: 19/04/2017 This study is important when introducing drug molecule in to clinical therapy. Combinatorial chemistry means the systemic and repetitive *For Correspondence covalent connection of different molecular entities i.e., with different building blocks. We are studying the principle, design of combinatorial Shaikh SM, Department of Pharmaceutics and chemistry. We used different approaches for creating chemical libraries Quality Assurance, Shree Santkrupa College and identification of active ingredients with different types and their of Pharmacy, Ghogaon-415 111, Karad, advantages and disadvantages. Further detailed study deals with methods Maharashtra, India, Tel: 02164257404. of combinatorial chemistry in which methods are responsible for formation of new molecule with the huge application of combinatorial chemistry with E-mail: [email protected] systemic and repetitive connection by chemical bonding. We also studied the biological activity of newly synthesized molecule against their targets. Keywords: Combinatorial chemistry, QSAR, Drug discovery INTRODUCTION Drug Discovery The fields of medicine include medicinal chemistry, pharmacology, pharmaceutical biotechnology by which drug entities are discovered. Many decants drugs were discovered for identifying the active ingredient from traditional entities discovery. Recently synthesized small entities, natural formulated products or extracts were screened in intact cells or whole materials to identify substances which are desirable for therapeutic action.
    [Show full text]
  • Mass Spectrometry in High Throughput Analysis
    Spectroscopy 17 (2003) 663–680 663 IOS Press Mass spectrometry in high throughput analysis Elizabeth Want a,b, Michael Greig c,BruceComptond, Ben Bolaños c and Gary Siuzdak a,b,∗ a The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA b Mass Consortium Corporation, 3030 Bunker Hill Street, San Diego, CA 92109, USA c Pfizer Global Research and Development – La Jolla Laboratories, Agouron Pharmaceuticals, Inc., 10770 Science Center Drive, San Diego, CA 92121, USA d Waters Corporation, 34 Maple Street, Milford, MA 01757, USA 1. Overview High throughput mass spectrometry has been motivated largely from recent developments in both chemistry and biology. For instance, in chemistry, the production of large populations of molecular li- braries increases the probability that novel compounds of practical value will be found, yet also requires that their identity be confirmed and purity assessed [1–6]. While many fields of research have been in- fluenced by this approach, the largest investment has come from the pharmaceutical, biotechnology and agrochemical arena. In the field of drug development, high throughput chemistry represents a conver- gence of chemistry with biology, made possible by fundamental advances in automation, such as that of mass spectrometry [7–19]. High throughput technology has even been extended to proteomics, where mass spectrometry is being used as a tool in rapid protein identification [20–22]. Electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry have become useful for qualitative, and more recently, quantitative analysis, aiding the development of mass spectrometry as a high throughput tool in these different fields (Fig.
    [Show full text]
  • Target Profile Prediction and Practical Evaluation of a Biginelli-Type Dihydropyrimidine Compound Library
    Pharmaceuticals 2011, 4, 1236-1247; doi:10.3390/ph4091236 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Article Target Profile Prediction and Practical Evaluation of a Biginelli-Type Dihydropyrimidine Compound Library Petra Schneider, Katharina Stutz †, Ladina Kasper †, Sarah Haller, Michael Reutlinger, Felix Reisen, Tim Geppert and Gisbert Schneider * Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Str. 10, CH-8093 Zurich, Switzerland † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +41-44-633-7438; Fax: +41-44-633-1379. Received: 26 August 2011; in revised form: 13 September 2011 / Accepted: 16 September 2011 / Published: 20 September 2011 Abstract: We present a self-organizing map (SOM) approach to predicting macromolecular targets for combinatorial compound libraries. The aim was to study the usefulness of the SOM in combination with a topological pharmacophore representation (CATS) for selecting biologically active compounds from a virtual combinatorial compound collection, taking the multi-component Biginelli dihydropyrimidine reaction as an example. We synthesized a candidate compound from this library, for which the SOM model suggested inhibitory activity against cyclin-dependent kinase 2 (CDK2) and other kinases. The prediction was confirmed in an in vitro panel assay comprising 48 human kinases. We conclude that the computational technique may be used for ligand-based in silico pharmacology studies, off-target prediction, and drug re-purposing, thereby complementing receptor-based approaches. Keywords: combinatorial chemistry; drug design; in silico pharmacology; kinase inhibitor; multi-component reaction; self-organizing map Pharmaceuticals 2011, 4 1237 1.
    [Show full text]